Effect of DHA on Proinflammatory Cytokines Including Platelets Activating Factor (PAF) in Preterm Neonates - Trial NCT04746885
Access comprehensive clinical trial information for NCT04746885 through Pure Global AI's free database. This phase not specified trial is sponsored by Ain Shams University and is currently Completed. The study focuses on Neonatal Disease. Target enrollment is 80 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Ain Shams University
Timeline & Enrollment
N/A
Sep 21, 2017
Jan 01, 2021
Primary Outcome
DEVELOPMENT OF NEC
Summary
The purpose of this study is to determine whether docosahexaenoic acid is effective in the
 prevention or reducing severity of necrotizing enterocolitis in preterm/low birth weight
 neonates.Necrotizing enterocolitis (NEC) is the most devastating gastrointestinal disease in
 neonates. The pathogenesis of NEC is not well defined but evidence strongly suggests that it
 is multifactorial . prematurity and enteral feeding are major risk factors for NEC. An
 excessive inflammatory response by the immature intestine to external stimuli, impaired
 intestinal barrier integrity and / or abnormal bacterial colonization are key factors
 implicated in pathophysiology of NEC.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04746885
Non-Device Trial